妇科恶性肿瘤术后激素替代治疗的研究进展

赵明明; 王天佑 综述; 王超 审校

doi:10.19401/j.cnki.1007-3639.2022.11.008

您当前的位置：

首页 >

文章列表页 >

妇科恶性肿瘤术后激素替代治疗的研究进展

综述 | 更新时间：2025-12-31

- 妇科恶性肿瘤术后激素替代治疗的研究进展
- Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer
- 中国癌症杂志 2022年32卷第11期页码：1098-1104
- 作者机构：
  
  复旦大学附属妇产科医院妇科，上海 200011
- 作者简介：
  
  [ "赵明明（ORCID: 0000-0002-7645-4768），硕士在读。" ]
  王超（ORCID: 0000-0003-4636-5104），博士，主任医师。
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.11.008
  中图分类号： R737.3
- 收稿：2022-06-25，
  
  修回：2022-08-03，
  
  纸质出版：2022-11-30
- 稿件说明：
移动端阅览
赵明明, 王天佑综述, 王超审校. 妇科恶性肿瘤术后激素替代治疗的研究进展[J]. 中国癌症杂志, 2022,32(11):1098-1104.

Mingming ZHAO, Tianyou WANG, Chao WANG. Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer[J]. China Oncology, 2022, 32(11): 1098-1104.
赵明明, 王天佑综述, 王超审校. 妇科恶性肿瘤术后激素替代治疗的研究进展[J]. 中国癌症杂志, 2022,32(11):1098-1104. DOI： 10.19401/j.cnki.1007-3639.2022.11.008.

Mingming ZHAO, Tianyou WANG, Chao WANG. Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer[J]. China Oncology, 2022, 32(11): 1098-1104. DOI： 10.19401/j.cnki.1007-3639.2022.11.008.

摘要

激素替代治疗（menopausal hormone therapy，MHT）是缓解绝经后患者更年期症状的有效疗法，妇科恶性肿瘤术后患者使用MHT的安全性和有效性是临床上持续关注的重点问题。本文回顾近5年妇科恶性肿瘤术后MHT的相关临床研究，综合结果表明，早期子宫内膜癌（endometrial cancer，EC）术后行MHT不增加复发风险，且有利于提高生活质量。上皮性卵巢癌（ovarian cancer，OC）患者术后MHT对无病生存期和总生存期无不利影响，但不建议用于卵巢性索间质肿瘤等非上皮性卵巢肿瘤。宫颈鳞状细胞癌术后MHT相对安全，但关于宫颈腺癌、外阴癌、阴道癌患者术后使用MHT的研究较少，目前暂无确切结论。本综述旨在更新对妇科恶性肿瘤术后激素治疗的认识，为临床上合理选择MHT方案提供参考，以进一步提高患者生活质量。

Abstract

Menopausal hormone therapy (MHT) is an effective therapy for alleviating menopausal symptoms in postmenopausal patients. Clinically

the safety and effectiveness of MHT in postoperative patients with gynecological malignant tumors are the most important. We reviewed the clinical studies on MHT after surgical treatment of gynecological malignant tumors in recent five years. The comprehensive results showed that MHT after surgical treatment of early endometrial cancer (EC) did not increase the risk of recurrence and improved the quality of life. Postoperative MHT has no adverse effect on disease-free survival and overall survival in patients with epithelial ovarian cancer (OC)

however it is not recommended for other non-epithelial ovarian tumors such as ovarian sex cord stromal tumor. MHT is relatively safe after surgical treatment of cervical squamous cell carcinoma

however there are few studies on the postoperative use of MHT in cervical adenocarcinoma

vulvar cancer and vaginal cancer patients

and no definite conclusions are available at present. This review aimed to update the understanding of postoperative hormone therapy for gynecological malignant tumors and provide reference for improving the patients’ life quality and selecting MHT regimen rationally.

关键词

Keywords

references

XIE M Q , CHEN R , REN M L . Chinese guidelines for menopausal management and menopausal hormone therapy (2018) [J ] . Chin J Obstet Gynecol , 2018 , 9 ( 06 ): 512 - 25 .

STABILE C , GOLDFARB S , BASER R E , et al. Sexual health needs and educational intervention preferences for women with cancer [J ] . Breast Cancer Res Treat , 2017 , 165 ( 1 ): 77 - 84 . DOI: 10.1007/s10549-017-4305-6 http://doi.org/10.1007/s10549-017-4305-6 https://doi.org/10.1007/s10549-017-4305-6 https://doi.org/10.1007/s10549-017-4305-6

KAGAN R S , KELLOGG-SPADT S , PARISH S J . Practical treatment considerations in the management of genitourinary syndrome of menopause [J ] . Drugs Aging , 2019 , 36 ( 10 ): 897 - 908 . DOI: 10.1007/s40266-019-00700-w http://doi.org/10.1007/s40266-019-00700-w

KOZMA B , PÓKA R , SIPOS A , et al. Short-term efficacy of vaginal CO 2 laser therapy as a treatment modality for genitourinary syndrome of menopause [J ] . Orv Hetil , 2019 , 160 ( 41 ): 1617 - 1622 . DOI: 10.1556/650.2019.31529 http://doi.org/10.1556/650.2019.31529 https://www.akademiai.com/doi/10.1556/650.2019.31529 https://www.akademiai.com/doi/10.1556/650.2019.31529

GERNIER F , GOMPEL A , ROUSSET-JABLONSKI C , et al. Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study [J ] . Gynecol Oncol , 2021 , 163 ( 3 ): 598 - 604 . DOI: 10.1016/j.ygyno.2021.10.001 http://doi.org/10.1016/j.ygyno.2021.10.001

MCNEIL M . Menopausal hormone therapy: understanding long-term risks and benefits [J ] . JAMA , 2017 , 318 ( 10 ): 911 - 913 . DOI: 10.1001/jama.2017.11462 http://doi.org/10.1001/jama.2017.11462

CHLEBOWSKI R T , ANDERSON G L , ARAGAKI A K , et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials [J ] . JAMA , 2020 , 324 ( 4 ): 369 - 380 . DOI: 10.1001/jama.2020.9482 http://doi.org/10.1001/jama.2020.9482 https://jamanetwork.com/journals/jama/fullarticle/2768806 https://jamanetwork.com/journals/jama/fullarticle/2768806

CHU K , SONG Y , CHATOOAH N D , et al. The use and discontinuation of hormone replacement therapy in women in South China [J ] . Climacteric , 2018 , 21 ( 1 ): 47 - 52 . DOI: 10.1080/13697137.2017.1397622 http://doi.org/10.1080/13697137.2017.1397622

WANG X M , CHEN Q Y , HUANG X , et al. Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression [J ] . Oncol Lett , 2017 , 13 ( 1 ): 57 - 62 . DOI: 10.3892/ol.2016.5424 http://doi.org/10.3892/ol.2016.5424

CHO H W , CHO H W , OUH Y T , et al. Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database [J ] . J Gynecol Oncol , 2019 , 30 ( 4 ): e51 . DOI: 10.3802/jgo.2019.30.e51 http://doi.org/10.3802/jgo.2019.30.e51 https://ejgo.org/DOIx.php?id=10.3802/jgo.2019.30.e51 https://ejgo.org/DOIx.php?id=10.3802/jgo.2019.30.e51

LIM S , KIM Y H , LEE K B , et al. The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients [J ] . J Gynecol Oncol , 2018 , 29 ( 5 ): e72 . DOI: 10.3802/jgo.2018.29.e72 http://doi.org/10.3802/jgo.2018.29.e72 https://ejgo.org/DOIx.php?id=10.3802/jgo.2018.29.e72 https://ejgo.org/DOIx.php?id=10.3802/jgo.2018.29.e72

DI DONATO V , PALAIA I , D’ANIELLO D , et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review [J ] . Oncology , 2020 , 98 ( 4 ): 195 - 201 . DOI: 10.1159/000505427 http://doi.org/10.1159/000505427

EDEY K A , RUNDLE S , HICKEY M . Hormone replacement therapy for women previously treated for endometrial cancer [J ] . Cochrane Database Syst Rev , 2018 , 5 : CD008830 .

BRENNAN A , BRENNAN D , REES M , et al. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer [J ] . Int J Gynecol Cancer , 2021 , 31 ( 3 ): 352 - 359 . DOI: 10.1136/ijgc-2020-002032 http://doi.org/10.1136/ijgc-2020-002032

Committee of Psoriasis, Dermatology Branch, Chinese Medical Association . Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition # [J ] . Int J Dermatol Venereol , 2020 , 3 ( 1 ): 14 - 26 . DOI: 10.1097/JD9.0000000000000074 http://doi.org/10.1097/JD9.0000000000000074 https://journals.lww.com/10.1097/JD9.0000000000000074 https://journals.lww.com/10.1097/JD9.0000000000000074

EELES R A , MORDEN J P , GORE M , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial [J ] . J Clin Oncol , 2015 , 33 ( 35 ): 4138 - 4144 . DOI: 10.1200/JCO.2015.60.9719 http://doi.org/10.1200/JCO.2015.60.9719

SAEAIB N , PEEYANANJARASSRI K , LIABSUETRAKUL T , et al. Hormone replacement therapy after surgery for epithelial ovarian cancer [J ] . Cochrane Database Syst Rev , 2020 , 1 : CD012559 .

LI D , DING C Y , QIU L H . Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis [J ] . Gynecol Oncol , 2015 , 139 ( 2 ): 355 - 362 . DOI: 10.1016/j.ygyno.2015.07.109 http://doi.org/10.1016/j.ygyno.2015.07.109

POWER L , LEFAS G , LAMBERT P , et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival [J ] . Obstet Gynecol , 2016 , 127 ( 5 ): 837 - 847 . DOI: 10.1097/AOG.0000000000001396 http://doi.org/10.1097/AOG.0000000000001396

ZHANG Y L , CHEN J H , LU W , et al. Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma [J ] . Chin Med J (Engl) , 2016 , 129 ( 11 ): 1316 - 1321 .

RAY-COQUARD I , MORICE P , LORUSSO D , et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2018 , 29 ( Suppl 4 ): iv1 -iv18. DOI: 10.1093/annonc/mdy001 http://doi.org/10.1093/annonc/mdy001 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316898 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316898

DELI T , OROSZ M , JAKAB A . Hormone replacement therapy in cancer survivors-review of the literature [J ] . Pathol Oncol Res , 2020 , 26 ( 1 ): 63 - 78 . DOI: 10.1007/s12253-018-00569-x http://doi.org/10.1007/s12253-018-00569-x https://doi.org/10.1007/s12253-018-00569-x https://doi.org/10.1007/s12253-018-00569-x

DEL CARMEN M G , RICE L W . Management of menopausal symptoms in women with gynecologic cancers [J ] . Gynecol Oncol , 2017 , 146 ( 2 ): 427 - 435 . DOI: S0090-8258(17)30954-X http://doi.org/S0090-8258(17)30954-X

REES M , ANGIOLI R , COLEMAN R L , et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis [J ] . Maturitas , 2020 , 134 : 56 - 61 . DOI: S0378-5122(20)30025-6 http://doi.org/S0378-5122(20)30025-6

ANGIOLI R , LUVERO D , ARMENTO G , et al. Hormone replacement therapy in cancer survivors: utopia? [J ] . Crit Rev Oncol Hematol , 2018 , 124 : 51 - 60 . DOI: S1040-8428(17)30267-6 http://doi.org/S1040-8428(17)30267-6

VARGIU V , AMAR I D , ROSATI A , et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature [J ] . Climacteric , 2021 , 24 ( 2 ): 120 - 127 . DOI: 10.1080/13697137.2020.1826426 http://doi.org/10.1080/13697137.2020.1826426

WANG J C M , BERNARD L , BOUTROSS-TADROSS O , et al. Estrogen receptor-positive adenocarcinoma of the cervix presenting during pregnancy: two case reports and review of the literature [J ] . Gynecol Oncol Rep , 2022 , 39 : 100916 .

LEE S A , BAIK S , CHUNG S H . Functional roles of female sex hormones and their nuclear receptors in cervical cancer [J ] . Essays Biochem , 2021 , 65 ( 6 ): 941 - 950 .

RICHARDSON A , WATSON L , PERSIC M , et al. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma [J ] . Post Reprod Health , 2021 , 27 ( 3 ): 167 - 173 . DOI: 10.1177/20533691211028518 http://doi.org/10.1177/20533691211028518 http://journals.sagepub.com/doi/10.1177/20533691211028518 http://journals.sagepub.com/doi/10.1177/20533691211028518

ADAMS T S , ROGERS L J , CUELLO M A . Cancer of the vagina: 2021 update [J ] . Int J Gynaecol Obstet , 2021 , 155 ( Suppl 1 ): 19 - 27 .

BUCCHI L , PIZZATO M , ROSSO S , et al. New insights into the epidemiology of vulvar cancer: systematic literature review for an update of incidence and risk factors [J ] . Cancers (Basel) , 2022 , 14 ( 2 ): 389 . DOI: 10.3390/cancers14020389 http://doi.org/10.3390/cancers14020389 https://www.mdpi.com/2072-6694/14/2/389 https://www.mdpi.com/2072-6694/14/2/389

STUTE P , STADLER A , HEUFELDER A . The impact of menopausal hormone therapy on overall mortality-a comprehensive review [J ] . Climacteric , 2020 , 23 ( 5 ): 447 - 459 . DOI: 10.1080/13697137.2020.1767568 http://doi.org/10.1080/13697137.2020.1767568 https://www.tandfonline.com/doi/full/10.1080/13697137.2020.1767568 https://www.tandfonline.com/doi/full/10.1080/13697137.2020.1767568

PINKERTON J V . Hormone therapy for postmenopausal women [J ] . N Engl J Med , 2020 , 382 ( 5 ): 446 - 455 . DOI: 10.1056/NEJMcp1714787 http://doi.org/10.1056/NEJMcp1714787 http://www.nejm.org/doi/10.1056/NEJMcp1714787 http://www.nejm.org/doi/10.1056/NEJMcp1714787

BABER R J , PANAY N , FENTON A , et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy [J ] . Climacteric , 2016, 19 ( 2 ): 109 - 150 . DOI: 10.3109/13697137.2015.1129166 http://doi.org/10.3109/13697137.2015.1129166 http://www.tandfonline.com/doi/full/10.3109/13697137.2015.1129166 http://www.tandfonline.com/doi/full/10.3109/13697137.2015.1129166

US PREVENTIVE SERVICES TASK FORCE , GROSSMAN D C , CURRY S J , et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US preventive services task force recommendation statement [J ] . JAMA , 2017 , 318 ( 22 ): 2224 - 2233 . DOI: 10.1001/jama.2017.18261 http://doi.org/10.1001/jama.2017.18261

SIMIN J , TAMIMI R M , CALLENS S , et al. Menopausal hormone therapy treatment options and ovarian cancer risk: a Swedish prospective population-based matched-cohort study [J ] . Int J Cancer , 2020 , 147 ( 1 ): 33 - 44 . DOI: 10.1002/ijc.32706 http://doi.org/10.1002/ijc.32706

VINOGRADOVA Y , COUPLAND C , HIPPISLEY-COX J . Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases [J ] . BMJ , 2020 , 371 : m3873 .

KOTSOPOULOS J , GRONWALD J , KARLAN B Y , et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers [J ] . JAMA Oncol , 2018 , 4 ( 8 ): 1059 - 1065 . DOI: 10.1001/jamaoncol.2018.0211 http://doi.org/10.1001/jamaoncol.2018.0211

MARCHETTI C , DE FELICE F , BOCCIA S , et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis [J ] . Crit Rev Oncol Hematol , 2018 , 132 : 111 - 115 . DOI: S1040-8428(18)30276-2 http://doi.org/S1040-8428(18)30276-2

VINOGRADOVA Y , COUPLAND C , HIPPISLEY-COX J . Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases [J ] . BMJ , 2019 , 364 : k4810 .

LIANG Y , JIAO H Y , QU L B , et al. Association between hormone replacement therapy and development of endometrial cancer: results from a prospective US cohort study [J ] . Front Med (Lausanne) , 2021 , 8 : 802959 .

CRANDALL C J , HOVEY K M , ANDREWS C A , et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study [J ] . Menopause , 2018 , 25 ( 1 ): 11 - 20 .

浏览量

2587

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2023年度妇科恶性肿瘤治疗进展及展望

2023年ESMO妇科肿瘤治疗最新进展及展望

2022年度妇科肿瘤诊治进展

2025 年度妇科恶性肿瘤年度进展盘点

外泌体中ISG15在卵巢癌铂类药物耐药中的作用及初步机制探讨